title: Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
abstract: OBJECTIVE
  To determine the efficacy of bevacizumab in patients with metastatic colorectal cancer (MCRC) who have failed prior chemotherapy without bevacizumab.
  
  
  METHODS
  Between March 2002 and June 2010, 40 patients in South Korea with MCRC who were treated with bevacizumab plus chemotherapy as a second or later-line treatment were analyzed retrospectively for their overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). The tumor responses were assessed using the Response Evaluation Criteria in Solid Tumors guidelines.
  
  
  RESULTS
  All of the patients had progressed under prior chemotherapy without bevacizumab. Three patients (7.5%) exhibited an ORR, twenty one patients (52.5%) exhibited stable disease (SD), and fifteen patients (37.5%) exhibited disease progression. The median duration of the OS and PFS were 14.0 mo and 6.13 mo respectively. The median OSs were 16.60, 14.07 and 13.00 mo for second-line, third-line and fourth- or later-line treatments, respectively. The median PFSs were 7.23, 7.30 and 3.87 mo for the second-line, third-line and fourth- or later-line treatments, respectively.
  
  
  CONCLUSIONS
  In patients with MCRC, bevacizumab combined chemotherapy may be beneficial during second- or later-line treatment.
authors.affiliation: Department of Internal Medicine, Kosin University College of Medicine, Busan 602-703, South Korea.
authors.forename: Lee Chun
authors.initials: LC
authors.lastname: Park
authors.forename: Ho Sup
authors.initials: HS
authors.lastname: Lee
authors.forename: Seong Hoon
authors.initials: SH
authors.lastname: Shin
authors.forename: Seun Ja
authors.initials: SJ
authors.lastname: Park
authors.forename: Moo In
authors.initials: MI
authors.lastname: Park
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Hyuk Chan
authors.initials: HC
authors.lastname: Kwon
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Baek
authors.forename: Young Jin
authors.initials: YJ
authors.lastname: Choi
authors.forename: Myoung Joo
authors.initials: MJ
authors.lastname: Kang
authors.forename: Yang Soo
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000473:pathology*; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D056910:Republic of Korea; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin